This Monday, the biotechnology company Moderna has taken another step in the fight against coronavirus. Following the announcement last week by other pharmaceutical companies about their respective vaccines, the US company has assured that its vaccine project, mRNA-12-73, presents an efficiency of 94.5%.
The process of making the vials takes place in the United States, but it does not end there: the last phase of it takes place in Spain. Specifically, in Alcobendas, at the headquarters of the Rovi Laboratories.
The agreement, in force for a few months, was captured last June, with the aim of carrying out the “Large-scale manufacturing of the filling and finishing of the candidate mRNA vaccine against COVID-19”, the company assured in a statement. Following the announcement, Rovi’s shares on the stock market soared to all-time highs, with a 9% growth. Since then, it has not stopped climbing.
Rovi, present in the vaccine preparation for Europe
In order to meet the objective, Rovi made the decision to acquire “a new production line and equipment for formulation, filling, automatic visual inspection and labeling “of vials. This supports the” production of hundreds of millions of doses for supply markets outside of the United States beginning in early 2021“.
In turn, Moderna explained her association with Rovi due to her “experience as a global manufacturer of pharmaceutical products and its expertise in filling and finishing”. With this agreement, Rovi entered the fight against the virus, since previously its only link was the possible use of some of its heparins with which to combat some effects derived from infection in sick patients.
“We are going to get that vaccine to all countries outside the United States.”, claimed at the time of the announcement the vice president of Rovi laboratories, Javier López, in Onda Madrid.
Visit of the Minister of Health
Just a few days ago, on November 11, the Minister of Health, Salvador Illa, visited the Rovi facilities together with the director of the Spanish Agency for Medicines and Health Products (AEMPS), María Jesús Lamas.
More than 1,500 people in its workforce, during this year 18 million doses of the flu vaccine have been manufactured at this headquarters and 120 million low molecular weight heparin.